This article is part of the supplement: Proceedings of the 13th Annual Meeting of the Collaborative Group of the Americas on Inherited Colorectal Cancer
Poster presentation
Colorectal cancer risk in patients with inflammatory bowel disease and Lynch syndrome
-
* Corresponding author: Melyssa Aronson maronson@mtsinai.on.ca
Dr. Zane Cohen Digestive Disease Clinical Research Centre, Mount Sinai Hospital, Toronto, Ontario, Canada
Hereditary Cancer in Clinical Practice 2010, 8(Suppl 1):P1 doi:10.1186/1897-4287-8-S1-P1
The electronic version of this article is the complete one and can be found online at: http://www.hccpjournal.com/content/8/S1/P1
| Published: | 25 May 2010 |
© 2010 Aronson et al; licensee BioMed Central Ltd.
Background
Chronic inflammatory bowel disease (IBD) and Lynch syndrome (LS) are associated with an increased risk for developing colorectal cancer (CRC). After 8-10 years of pan-ulcerative colitis (DC), the risk of CRC is 2%, increasing by 0.5-1.0% annually. LS has been associated with a 60-80% lifetime risk of CRC. It is unclear whether individuals diagnosed with both IBD and LS would have a cumulative risk or earlier age of onset of CRC based on their diagnoses.
Method
Patients with IBD and a germline mismatch repair gene (MMR) mutation were identified through the Familial Gastrointestinal Cancer Registry at Mount Sinai Hospital in Toronto, Canada. Information on their IBD diagnosis, colorectal screening/surgery, medication use, family history and genetic test results were collected (Table 1).
Results
Five of 329 (1.5%) individuals with germline MMR mutations reported having a history of IBD.
Conclusions
Concurrent IBD and LS did not appear to predispose to early-onset CRC in our small case series.